Using a mouse model for NASH-related HCC, they showed that continuous administration of the DPP4 inhibitor to mice started around the time of NASH development did not improve the parameter of NASH, but did reduce liver tumor volume and number and increase the infiltration of activated NK cells to both the tumor and non-tumor liver [77]. This evidence concerns the gene DPP4 and metabolic dysfunction-associated steatohepatitis.